2024
Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma.
Wu H, Sukhanova M, Tang H, Lu X, Zhong M, Deshpande H, Pollack S, Laskin W, Alexiev B. Use of Mitotic Activity and the Size of Any Dedifferentiated Component for Risk Assessment in MDM2-Amplified Liposarcoma. Archives Of Pathology & Laboratory Medicine 2024 PMID: 39164013, DOI: 10.5858/arpa.2024-0098-oa.Peer-Reviewed Original ResearchAtypical lipomatous tumor/well-differentiated liposarcomaMDM2-amplified liposarcomasDedifferentiated componentDedifferentiated liposarcomaAdverse eventsMitotic countLocal recurrence statusMDM2 copy numberAssociated with adverse eventsLog-rank testOverall tumor volumeUnivariate logistic regressionChromosome 12q13-15Statistically significant associationPercentage of cellsTumor dimensionTumor volumeTumor sizeMDM2 proto-oncogeneClinicopathological characteristicsPathology reportsGrade 3Recurrence statusUnivariate analysisMultivariate regression model
2013
Outcomes for stage IVA squamous cell carcinoma of the oral cavity according to staging subtypes.
Marrone K, Otremba M, Groisberg R, Deshpande H, Crawford F, Acevedo-Gadea C, Gould Rothberg BE, Judson B, Morgensztern D. Outcomes for stage IVA squamous cell carcinoma of the oral cavity according to staging subtypes. Journal Of Clinical Oncology 2013, 31: 6076-6076. DOI: 10.1200/jco.2013.31.15_suppl.6076.Peer-Reviewed Original ResearchSquamous cell carcinomaStage IVAOverall survivalCell carcinomaOral cavityStage IVA squamous cell carcinomaIVA squamous cell carcinomaPatients meeting inclusion criteriaProportional hazards regression modelsLymph node categoryEnd Results (SEER) databaseLymph node statusKaplan-Meier methodLog-rank testHazards regression modelsMost clinical trialsCombination of tumorSubtypes of patientsMeeting inclusion criteriaSignificant differencesMost patientsIndependent predictorsNode statusResults databaseStage subgroups